Stocktwits4g fa · leggi qui →
These 2 Biotech Stocks Hit New 52-Week Highs Today – And CORT Clocked Its Best Day In Nearly 16 Months
Corcept Therapeutics and Anika Therapeutics received Wall Street support after reporting strong second-quarter results and sharply raising their full-year 2026 outlook.…
Zacks4g fa · leggi qui →
CORT Q2 Earnings & Revenues Beat Estimates, 2026 Outlook Raised
Corcept tops Q2 earnings estimates as Korlym growth and a strong Lifyorli launch lift revenues, prompting a higher 2026 top-line outlook.…
GuruFocus.com4g fa · leggi qui →
Corcept Therapeutics Inc (CORT) (Q2 2026) Earnings Call Highlights: Record Revenue and ...
Revenue surged 32% to $256.1 million, driven by strong Cushing's syndrome sales and a successful Lifyorli launch, as the company raises full-year guidance.…
Zacks4g fa · leggi qui →
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates
Corcept (CORT) delivered earnings and revenue surprises of +1,000.00% and +18.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?…
MarketBeat4g fa · leggi qui →
Corcept Therapeutics Q2 Earnings Call Highlights
Corcept Therapeutics (NASDAQ:CORT) reported second-quarter 2026 revenue of $256.1 million, up 32% from the prior-year period, as sales from its Cushing’s syndrome franchise increased and its newly lau…
StockStory4g fa · leggi qui →
Corcept (NASDAQ:CORT) Reports Bullish Q2 CY2026, Stock Jumps 17.4%
Biopharma company Corcept Therapeutics (NASDAQ:CORT) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 31.7% year on year to $256.1 million. The company’s full-year r…
StockStory5g fa · leggi qui →
Spotting Winners: Corcept (NASDAQ:CORT) And Branded Pharmaceuticals Stocks In Q1
Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded pharmaceuticals earnings season.…
StockStory6g fa · leggi qui →
Corcept (CORT) Q2 Earnings: What To Expect
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Wednesday after market hours. Here’s what to expect.…
StockStory6g fa · leggi qui →
Why Corcept (CORT) Stock Is Down Today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 2.9% in the morning session after Wolfe Research downgraded the stock to 'Underperform' from 'Peerperform', citi…
Simply Wall St.9g fa · leggi qui →
Corcept Therapeutics (CORT) Lifted Earnings Outlook, Is The Stock Now Overvalued?
Corcept Therapeutics (CORT) has attracted fresh attention after a sharp improvement in its earnings outlook, with full year earnings estimates rising significantly and analyst sentiment turning more c…